Breast Cancer Clinical Roundup

News Articles

(MassDevice) July 9, 2020 - Therapixel today said it received FDA 510(k) clearance for its MammoScreen artificial intelligence-used software.
(IU School of Medicine) July 9, 2020 - Indiana University School of Medicine researchers have discovered that the presence of circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) in the plasma of women's blood who have undergone chemotherapy prior to surgery for the treatment of stage 1, 2 or 3 triple negative breast cancer...
(ESMO) July 9, 2020 - The exploratory subgroup analysis of the KAMILLA trial represents the largest reported cohort of patients with HER2-positive metastatic breast cancer and brain metastases treated with T-DM1 in a prospective setting.
(Immunomedics) July 6, 2020 - Immunomedics, Inc. today announced that the confirmatory Phase 3 ASCENT study of Trodelvy (sacituzumab govitecan-hziy) met its primary endpoint of progression-free survival (PFS), as well as key secondary endpoints in brain metastasis negative patients with mTNBC who have previously received at least two...
(Yale News) July 1, 2020 - In a new Yale Cancer Center (YCC) study, researchers have demonstrated that a higher percentage of women with breast cancer had their disease diagnosed at an early stage in states with expanded Medicaid coverage through the Affordable Care Act (ACA). No such change was seen in states that didn’t expand...
View all breast cancer news


Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center, and Nancy Lin, MD, Associate Professor of Medicine, Harvard Medical School Associate Chief, Division of Breast Oncology Dana-Farber Cancer Institute, discuss novel agents and recent clinical developments in breast cancer

Clinical Roundtables

A panel of three breast cancer experts looked at some of the big studies at ASCO 2020 and discussed treatment advances and setbacks of key data in the area of CDK4/6 inhibition, HER2-positive disease, and immunotherapy in breast cancer at a recent roundtable.